These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 6648902)
1. Agonist-specific refractory states of bovine platelets-disappearance of synergism in aggregation. Imada T; Saito Y; Shimada H; Inada Y Thromb Res; 1983 Sep; 31(6):807-15. PubMed ID: 6648902 [TBL] [Abstract][Full Text] [Related]
2. Whole blood platelet aggregation in humans and animals: a comparative study. Soloviev MV; Okazaki Y; Harasaki H J Surg Res; 1999 Apr; 82(2):180-7. PubMed ID: 10090827 [TBL] [Abstract][Full Text] [Related]
3. Shape change and aggregation of blood platelets: interaction between the effects of adenosine and diphosphate, 5-hydroxytryptamine and adrenaline. Michal F; Motamed M Br J Pharmacol; 1976 Feb; 56(2):209-18. PubMed ID: 1252669 [TBL] [Abstract][Full Text] [Related]
5. Alteration of release and role of adenosine diphosphate and thromboxane A2 during collagen-induced aggregation of platelets from cattle with Chediak-Higashi syndrome. Honda N; Ohnishi K; Fujishiro T; Ikeda M; Ito K Am J Vet Res; 2007 Dec; 68(12):1399-406. PubMed ID: 18052747 [TBL] [Abstract][Full Text] [Related]
7. [Effect of calcium, thrombin and nucleotides (ADP, cAMP, cGMP) on blood platelet glycolysis and energy metabolism]. Nikulin AA Farmakol Toksikol; 1980; 43(5):585-90. PubMed ID: 6256208 [TBL] [Abstract][Full Text] [Related]
8. Effects of ketanserin and mepyramine on platelet aggregation and on the uptake of 5-hydroxytryptamine into platelets. Bevan J; Heptinstall S Thromb Res; 1983 Jun; 30(5):415-23. PubMed ID: 6612677 [TBL] [Abstract][Full Text] [Related]
9. Recombinant insulin-like growth factor-1 modulates aggregation in human platelets via extracellular calcium. Motani AS; AnggÄrd EE; Ferns GA Life Sci; 1996; 58(15):PL269-74. PubMed ID: 8614272 [TBL] [Abstract][Full Text] [Related]
10. Regulation of human platelet activation--analysis of cyclooxygenase and cyclic AMP-dependent pathways. Krishnamurthi S; Westwick J; Kakkar VV Biochem Pharmacol; 1984 Oct; 33(19):3025-35. PubMed ID: 6091666 [TBL] [Abstract][Full Text] [Related]
11. Characteristics of the synergistic actions of platelet agonists. Huang EM; Detwiler TC Blood; 1981 Apr; 57(4):685-91. PubMed ID: 7470619 [TBL] [Abstract][Full Text] [Related]
12. Pathways responsible for platelet hypersensitivity in rats with diabetes. I. Streptozocin-induced diabetes. Winocour PD; Kinlough-Rathbone RL; Mustard JF J Lab Clin Med; 1986 Feb; 107(2):148-53. PubMed ID: 3080538 [TBL] [Abstract][Full Text] [Related]
13. Synergistic responses in human platelets. Comparison between aggregation, secretion and cytosolic Ca2+ concentration. Thompson NT; Scrutton MC; Wallis RB Eur J Biochem; 1986 Dec; 161(2):399-408. PubMed ID: 3490977 [TBL] [Abstract][Full Text] [Related]
14. N-Ethylmaleimide induces disaggregation of platelets preaggregated by ADP and thrombin and decreases cytoplasmic calcium level. Samal AB; Loiko EN Biochemistry (Mosc); 2000 Feb; 65(2):230-6. PubMed ID: 10713553 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of platelet aggregation by ethanol in vitro shows specificity for aggregating agent used and is influenced by platelet lipid composition. Fenn CG; Littleton JM Thromb Haemost; 1982 Aug; 48(1):49-53. PubMed ID: 6813995 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of agonist-induced platelet aggregation, Ca2+ mobilization and granule secretion by guanosine 5'-[beta-thio]diphosphate and GDP in intact platelets. Evidence for an inhibitory mechanism unrelated to the inhibition of G-protein-GTP interaction. Krishnamurthi S; Patel Y; Kakkar VV Biochem J; 1988 Feb; 250(1):209-14. PubMed ID: 3355512 [TBL] [Abstract][Full Text] [Related]